August 24, 2015
Article
Recent therapeutic advances have almost doubled the survival of patients with metastatic pancreatic cancer, and the availability of highly active chemotherapy regimens is making personalized medicine a reality.
April 10, 2014
Video
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses the utility of CA 19-9 in patients with pancreatic cancer.
March 18, 2014
Video
Wen Wee Ma, MBBS, associate professor of oncology, Department of Medicine, Roswell Park Cancer Institute, discusses interrupting the FGFR signaling pathway in pancreatic cancer.
January 08, 2014
Article
LDK378 is a highly selective and potent inhibitor of ALK, and has demonstrated preclinical antitumor activity against tumors with acquired crizotinib resistance. In a phase I trial, LDK378 induced tumor response in 70% of patients with crizotinib-resistant NSCLC.